Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Poster. Contemporary art collage. Blue and yellow hands peeking out of black holes in space to make a deal. Abstract vibrant artwork. Concept of pop art, positive emotions. Minimal art design.

Venture capitalists

Lilly Partners With a16z on $500M VC Fund for Early-Stage Biotechs

The Biotech Ecosystem Venture Fund will combine the sourcing capabilities of venture capital firm Andreessen Horowitz (a16z) with Eli Lilly’s expertise in R&D—plus half a billion in capital from the Big Pharma.

January 10, 2025

1 min read

Annalee Armstrong

Heart human anatomy anatomical pottery neutral backgrounds soft tones beige brown background 3d illustration render digital rendering

Cardiovascular disease

Marea Posts Positive Phase II Data for Remnant Cholesterol Lowering mAb

Research has shown remnant cholesterol is a significant factor in cardiovascular disease risk.

January 10, 2025

1 min read

Kate Goodwin

Sign in front of Pfizer in Quebec, Canada

Bladder cancer

Pfizer’s Subcutaneous PD-1 Blocker Aces Phase III in Bladder Cancer, Carves Niche Versus Keytruda

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor indicated in combination with BCG for high-risk non-muscle invasive bladder cancer patients who had not previously undergone BCG treatment.

January 10, 2025

2 min read

Tristan Manalac

Concept of money prize. Vector illustration. Halftone hand holds bouquet of money flowers. Gift prize, donation, earnings, bonus or cashback concept. Retro poster or banner. Creative trend collage.

Drug pricing

Part D Drugs Almost Doubled in Cost Since Launch, Underscoring Importance of IRA: AARP

Concurrently, a preprint from the industry-backed Vital Transformation found a 50% drop in company investments into small-molecule drug development.

January 10, 2025

3 min read

Tristan Manalac

Pictured: Eli Lilly's headquarters in Indianapolis

Collaboration

Lilly Makes $780M+ IPF Play with Mediar Partnership

Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early studies have found to be safe and capable of engaging its target.

January 10, 2025

2 min read

Tristan Manalac

Pictured: Boehringer Ingelheim sign on a building/

Collaboration

Boehringer Ingelheim Expands Cancer Pipeline With Back-to-Back Antibody Deals

On Thursday, Boehringer Ingelheim announced a partnership with Synaffix to advance antibody-drug conjugates and exercised its fourth license option under a 2013 collaboration with Oxford BioTherapeutics.

January 10, 2025

2 min read

Tristan Manalac

Banner Successful Launch New Idea Cartoon Flat. Incandescent in Form Rocket Takes off from Large Box. Man and Woman Rejoice at Launch New Successful Idea or Project. Vector Illustration.

Startups

GSK-backed Ouro Launches With $120M to ‘Reset’ the Immune System

Ouro is planning to leverage T cell engagers to deplete B cells and “reset” the immune system to treat immune-mediated diseases.

January 10, 2025

2 min read

Tristan Manalac

Conceptual business illustration of upcoming business problem metaphor with falling domino and businessman silhouette. Minimalistic vector eps 10 illustration

ALS

HEALEY ALS Trial Serves Up More Disappointment as Denali, AbbVie/Calico Fail

Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the latest setbacks for the controversial platform trial, the results from which have largely mirrored the dismal success rate in ALS overall.

January 10, 2025

5 min read

Heather McKenzie